Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Trial Assessing Safety and Preliminary Efficacy of High-Dose Intravenous Ascorbic Acid and Decitabine in TET2 -Mutant Chronic Myelomonocytic Leukemia

Kristen B. McCullough, Zhuoer Xie, Terra L. Lasho, Christy Finke, Jenna A. Fernandez, Michelle Renee Amundson, Betsy R. LaPlant, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6699.

https://doi.org/10.1182/blood-2024-203486

Published: 2024

Journal Articles

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Yucai Wang, Han W. Tun, Betsy R. LaPlant, Rebecca L. King, Ivana N. Micallef, Madiha Iqbal, Allison C. Rosenthal, Stephen M. Ansell, Jose C. Villasboas Bisneto, Arushi Khurana, Gita Thanarajasingam, Thomas M. Habermann, Javier L. Munoz, Paul J. Hampel, Patrick B. Johnston, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 580.

https://doi.org/10.1182/blood-2024-200206

Published: 2024

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Nancy L. Bartlett, Brian A. Costello, Betsy R. LaPlant, Stephen M. Ansell, John G. Kuruvilla, Craig B. Reeder, Lim S. Thye, Daniel M. Anderson, Kilannin Krysiak, Cody Ramirez, Jing Qi, Barry A. Siegel, Malachi Griffith, Obi L. Griffith, Felicia Gomez, Todd A. Fehniger

Blood (2018) 131 (2): 182–190.

https://doi.org/10.1182/blood-2017-09-804641

Published: 2018

Includes: Supplemental data

Journal Articles

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Blood (2017) 130 (10): 1198–1204.

https://doi.org/10.1182/blood-2017-05-782961

Published: 2017

Includes: Supplemental data

Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Blood (2017) 129 (26): 3419–3427.

https://doi.org/10.1182/blood-2017-02-765685

Published: 2017

Includes: Supplemental data

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Ayed O. Ayed, MD, Annalisa Chiappella, MD, Grzegorz S. Nowakowski, MD, Federica Cavallo, MD, Angela Giovanna Congiu, MD, Gianluca Gaidano, MD PhD, Levi Pederson, Betsy R. Laplant, MS, William R. Macon, MD, Gerardo Musuraca, MD, Alessandro Re, MD, Michele Spina, Thomas E. Witzig, MD, Umberto Vitolo

Blood (2016) 128 (22): 3033.

https://doi.org/10.1182/blood.V128.22.3033.3033

Published: 2016

Journal Articles

Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, MD, Betsy R. Laplant, MS, Levi Pederson, Matthew J Maurer, MS, William R. Macon, MD, Rebecca L King, MD, James Storhoff, Shannon Dennis, Anita K. Gandhi, PhD, Anjan Thakurta, PhD, Patrick R. Hagner, Lisa Rimsza, MD, Thomas M. Habermann, James R Cerhan, MD PhD, Thomas E. Witzig, MD

Blood (2016) 128 (22): 3035.

https://doi.org/10.1182/blood.V128.22.3035.3035

Published: 2016

Journal Articles

Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma

Francis K Buadi, MD, Morie A. Gertz, MD, Betsy R. Laplant, MS, Alese Halvorson, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, David Dingli, MD PhD FRCP, Prashant Kapoor, MD, Wilson I Gonsalves, MD, Teresa Miceli, RN, Eva Brandes, RN, Scott L Stafford, MD, James A Martenson, MD, William J Hogan, MBChB, Shaji K. Kumar, MD

Blood (2016) 128 (22): 2267.

https://doi.org/10.1182/blood.V128.22.2267.2267

Published: 2016

Journal Articles

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Jun Yin, PhD, Betsy R. Laplant, MS, Geoffrey L. Uy, MD, Guido Marcucci, MD, William Blum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra Mandrekar, PhD

Blood (2016) 128 (22): 214.

https://doi.org/10.1182/blood.V128.22.214.214

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Ayed O. Ayed, MD, Levi Pederson, William R. Macon, MD, Betsy R. Laplant, MS, Craig B. Reeder, MD, James M. Foran, MD, Garth Nelson, Candido E. Rivera, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 5322.

https://doi.org/10.1182/blood.V128.22.5322.5322

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Blood (2016) 128 (22): 4392.

https://doi.org/10.1182/blood.V128.22.4392.4392

Published: 2016

Journal Articles

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Blood (2016) 128 (20): 2415–2422.

https://doi.org/10.1182/blood-2016-05-717769

Published: 2016

Journal Articles

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

Patrick B. Johnston, MD PhD, Betsy R. Laplant, MS, Ellen D. McPhail, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Joseph P. Colgan, MD, Grzegorz S. Nowakowski, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD

Blood (2015) 126 (23): 813.

https://doi.org/10.1182/blood.V126.23.813.813

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood (2015) 126 (23): 3050.

https://doi.org/10.1182/blood.V126.23.3050.3050

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Blood (2014) 124 (21): 4780.

https://doi.org/10.1182/blood.V124.21.4780.4780

Published: 2014

Journal Articles

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Tait D. Shanafelt, MD, Betsy R. LaPlant, MS, Timothy G Call, MD, Daniel Nikcevich, MD PhD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Adam Pettinger, Daniel L. Van Dyke, PhD, Diane F. Jelinek, Curtis A. Hanson, MD, Neil E. Kay, MD

Blood (2014) 124 (21): 4673.

https://doi.org/10.1182/blood.V124.21.4673.4673

Published: 2014

NARROW

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Phase II Trial Assessing Safety and Preliminary Efficacy of High-Dose Intravenous Ascorbic Acid and Decitabine in TET2 -Mutant Chronic Myelomonocytic Leukemia

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only